Zeta NKX3.1 Antibody. Zeta’s recombinant mouse antibody recognizes NKX3.1, a prostate-specific gene encoding a transcription factor essential in normal prostate development and carcinogenesis. NKX3.1 is a prostatic tumor suppressor gene located on chromosome 8p21.2, which frequently undergoes a loss of heterozygosity. NKX3.1 expression is highly restricted in prostate epithelial cells and, therefore, can be used as a diagnostic biomarker for prostate cancer and other metastatic lesions of prostatic origin. Furthermore, NKX3.1 shows better sensitivity than Prostate-Specific Antigen (PSA) for identifying metastatic prostatic adenocarcinoma. As a result, immunohistochemical staining of NKX3.1, along with other prostate-restricted markers, may be valuable for the definitive determination of prostatic origin in poorly differentiated metastatic carcinomas.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.